# EDGAR Filing Document

**Accession Number:** 0002075068
**File Stem:** 0000000000-25-008632
**Filing Date:** 2025-8
**Character Count:** 5675
**Document Hash:** 6b74d1c1cdd1f1aa5917a595c0c38597
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008632.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0000000000-25-008632

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250815

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Invest Green Acquisition Corp
- **CENTRAL INDEX KEY:** 0002075068
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288875

**BUSINESS ADDRESS:**
- **STREET 1:** 19215 SE 24TH STREET, SUITE # 106-159
- **STREET 2:** C/O INVEST GREEN ACQUISITION CORPORATION
- **CITY:** CAMAS
- **STATE:** WA
- **ZIP:** 98607
- **BUSINESS PHONE:** 332-275-5814

**MAIL ADDRESS:**
- **STREET 1:** 19215 SE 24TH STREET, SUITE # 106-159
- **STREET 2:** C/O INVEST GREEN ACQUISITION CORPORATION
- **CITY:** CAMAS
- **STATE:** WA
- **ZIP:** 98607
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-066717

## Text-Extract

```

                                                            August 15, 2025

Andrew McLean
Chief Executive Officer and Director
Invest Green Acquisition Corporation
445 Park Avenue, 9th Floor
New York, NY 10022

       Re: Invest Green Acquisition Corporation
           Registration Statement on Form S-1
           Filed July 22, 2025
           File No. 333-288875
Dear Andrew McLean:

       We have reviewed your registration statement and have the following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Cover Page

1.     Please revise your cover page and where else you disclose that if you
seek
       shareholder approval for an extension, holders of public shares will be
offered an
       opportunity to vote on the extension and to redeem their shares    to
disclose whether
       they can redeem their shares regardless of whether they abstain, vote
for or vote
       against the proposed extension.
Summary
Business Strategy, page 7

2.     Please revise under this heading where you discuss your acquisition
strategy to also
       disclose, as you do on page 106, that you are focusing on completing a
business
       combination with companies in the rare earth materials and nuclear
energy industries.
 August 15, 2025
Page 2
Initial Business Combination, page 10

3.     Please revise to also disclose the amount of public shares sold in the
IPO that would
       have to affirmatively vote for the business combination in order for it
to be
       consummated.
Sponsor Information, page 13

4.     Please revise to disclose the experience of the SPAC sponsor, its
affiliates and any
       promoters in organizing special purpose acquisition companies and the
extent to
       which the SPAC sponsor, its affiliates and the promoters are involved in
other special
       purpose acquisition companies. Refer to Item 1603(a)(3) of Regulation
S-K.
Risk Factors
We may not be able to complete an initial business combination because such
initial business
combination may be subject..., page 66

5.     Please revise to disclose whether your sponsor is, is controlled by, has
any members
       who are or has substantial ties with, a non-U.S. person. If so, please
also discuss how
       this fact could impact your ability to complete your initial business
combination.
Dilution, page 92

6.     It appears that the titles    Net proceeds from this offering and the
sale of the private
       placement shares    and    Plus: Offering costs accrued for or paid in
advance, excluded
       from tangible book value    have been reversed for the amounts presented
in the
       respective line items. Please advise or revise.
Capitalization, page 94

7.     Please revise to provide footnotes which quantify and describe the
adjustments that
       impacted your additional paid in capital and accumulated deficit
balances.
Principal Shareholders, page 146

8.     Please revise to reflect the interests in the founder shares that will
be transferred to
       Mssrs. Campbell and Krawchuk and your independent directors or advise.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Eric Atallah at 202-551-3663 or Kevin Vaughn at
202-551-3494 if you
have questions regarding comments on the financial statements and related
matters. Please
 August 15, 2025
Page 3

       contact Daniel Crawford at 202-551-7767 or Alan Campbell at 202-551-4224
with
any other questions.

                                                       Sincerely,

                                                       Division of Corporation
Finance
                                                       Office of Life Sciences
cc:   Tricia Branker, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._